{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:05:20Z","timestamp":1784912720746,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014361","name":"Hubei University of Medicine","doi-asserted-by":"publisher","award":["2016QDJZR22"],"award-info":[{"award-number":["2016QDJZR22"]}],"id":[{"id":"10.13039\/501100014361","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.bbrc.2020.06.133","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T14:00:43Z","timestamp":1596117643000},"page":"142-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Preclinical evidence that MNK\/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma"],"prefix":"10.1016","volume":"530","author":[{"given":"Sen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8129-3786","authenticated-orcid":false,"given":"Juan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2020.06.133_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0344-0338(86)80001-2","article-title":"Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics","volume":"181","author":"Thoenes","year":"1986","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.bbrc.2020.06.133_bib2","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nature reviews. Disease primers"},{"key":"10.1016\/j.bbrc.2020.06.133_bib3","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.euo.2019.09.002","article-title":"First-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"2","author":"Hahn","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.bbrc.2020.06.133_bib4","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2020.06.133_bib5","article-title":"Temsirolimus versus pazopanib (TemPa) in patients with advanced clear-cell renal cell carcinoma and poor-risk features: a randomized phase II trial","author":"Tannir","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.bbrc.2020.06.133_bib6","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S1470-2045(19)30510-8","article-title":"Renal cell carcinoma treatment after first-line combinations","volume":"20","author":"Porta","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2020.06.133_bib7","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.1128\/MCB.24.15.6539-6549.2004","article-title":"Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development","volume":"24","author":"Ueda","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bbrc.2020.06.133_bib8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cyto.2016.01.024","article-title":"Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia","volume":"89","author":"Kosciuczuk","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.bbrc.2020.06.133_bib9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1146\/annurev.biochem.68.1.913","article-title":"eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation","volume":"68","author":"Gingras","year":"1999","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bbrc.2020.06.133_bib10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0959-440X(03)00009-5","article-title":"Eukaryotic translation initiation factors and regulators","volume":"13","author":"Sonenberg","year":"2003","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.bbrc.2020.06.133_bib11","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1158\/0008-5472.CAN-07-0752","article-title":"Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors","volume":"67","author":"Larsson","year":"2007","journal-title":"Canc. Res."},{"key":"10.1016\/j.bbrc.2020.06.133_bib12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.18632\/oncotarget.453","article-title":"Targeting Mnks for cancer therapy","volume":"3","author":"Hou","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2020.06.133_bib13","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1158\/0008-5472.CAN-10-3298","article-title":"Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases","volume":"71","author":"Konicek","year":"2011","journal-title":"Canc. Res."},{"key":"10.1016\/j.bbrc.2020.06.133_bib14","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1182\/blood-2013-01-477216","article-title":"Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors","volume":"121","author":"Altman","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bbrc.2020.06.133_bib15","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.cellsig.2016.06.005","article-title":"Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy","volume":"28","author":"Grzmil","year":"2016","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bbrc.2020.06.133_bib16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.biopha.2016.09.038","article-title":"Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma","volume":"84","author":"Liu","year":"2016","journal-title":"Biomedicine & pharmacotherapy\u00a0= Biomedecine & pharmacotherapie"},{"key":"10.1016\/j.bbrc.2020.06.133_bib17","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1186\/s40064-016-3153-x","article-title":"Niclosamide suppresses renal cell carcinoma by inhibiting Wnt\/beta-catenin and inducing mitochondrial dysfunctions","volume":"5","author":"Zhao","year":"2016","journal-title":"SpringerPlus"},{"key":"10.1016\/j.bbrc.2020.06.133_bib18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Canc. Res."},{"key":"10.1016\/j.bbrc.2020.06.133_bib19","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.bbrc.2016.01.046","article-title":"Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K\/Akt\/mTOR signaling pathway","volume":"470","author":"Liu","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2020.06.133_bib20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12943-016-0565-8","article-title":"Choosing the right cell line for renal cell cancer research","volume":"15","author":"Brodaczewska","year":"2016","journal-title":"Mol. Canc."},{"key":"10.1016\/j.bbrc.2020.06.133_bib21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.semcancer.2012.06.004","article-title":"Current and future systemic treatments for renal cell carcinoma","volume":"23","author":"Fisher","year":"2013","journal-title":"Semin. Canc. Biol."},{"key":"10.1016\/j.bbrc.2020.06.133_bib22","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nprot.2010.6","article-title":"In\u00a0vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract","volume":"5","author":"Arnaoutova","year":"2010","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bbrc.2020.06.133_bib23","doi-asserted-by":"crossref","first-page":"13984","DOI":"10.1073\/pnas.1008136107","article-title":"Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development","volume":"107","author":"Ueda","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2020.06.133_bib24","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1101\/gad.1604407","article-title":"Dissecting eIF4E action in tumorigenesis","volume":"21","author":"Wendel","year":"2007","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbrc.2020.06.133_bib25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10456-014-9420-y","article-title":"Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions","volume":"17","author":"Vasudev","year":"2014","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bbrc.2020.06.133_bib26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1158\/1535-7163.MCT-15-0170","article-title":"Preclinical evidence that trametinib enhances the response to antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma","volume":"15","author":"Bridgeman","year":"2016","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.bbrc.2020.06.133_bib27","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.2174\/0929867324666170203123427","article-title":"Mitogen-activated protein kinase (MAPK) interacting kinases 1 and 2 (MNK1 and MNK2) as targets for cancer therapy: recent progress in the development of MNK inhibitors","volume":"24","author":"Dreas","year":"2017","journal-title":"Curr. Med. Chem."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20313516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20313516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:25:17Z","timestamp":1784910317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X20313516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0006291X20313516"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.06.133","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evidence that MNK\/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.06.133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}